Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long‐term 9‐year follow‐up of 134 patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|5|E95-E96

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.5, 2015-05, pp. : E95-E96

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Follow-Up of Chronic Hepatitis C Patients Treated with Interferon-Alpha: Risk of Cirrhosis and Hepatocellular Carcinoma in a Single Center over 10 Years

By  

Intervirology, Vol. 58, Iss. 1, 2015-01 ,pp. : 14-21

Karger

Access to resources Recommend Favorite

Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4284-4289

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

By  

Acta Haematologica, Vol. 135, Iss. 3, 2015-11 ,pp. : 133-139

Karger

Access to resources Recommend Favorite

Long‐term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 57, Iss. 3, 2018-03 ,pp. : 332-338

John Wiley & Sons Inc

Access to resources Recommend Favorite

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up

By  

CANCER, Vol. 121, Iss. 10, 2015-05 ,pp. : 1637-1644

John Wiley & Sons Inc

Access to resources Recommend Favorite